Related Experiment Video
Updated: Jul 12, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
A Novel Cytochrome P450 2E1 Inhibitor Q11 Is Effective on Lung Cancer via Regulation of the Inflammatory
Lin Jia1, Fei Gao1, Guiming Hu1
1Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, Henan, 450001, China.
Abstract:
Lung cancer is the leading cause of death among all cancers. A persistent chronic inflammatory microenvironment is highly correlated with lung cancer. However, there are no anti-inflammatory agents effective against lung cancer. Cytochrome P450 2E1 (CYP2E1) plays an important role in the inflammatory response. Here, it is found that CYP2E1 is significantly higher in the peritumoral tissue of non-small cell lung cancer (NSCLC) patients and lung tumor growth is significantly impeded in Cyp2e1-/- mice. The novel CYP2E1 inhibitor Q11, 1-(4-methyl-5-thialzolyl) ethenone, is effective in the treatment of lung cancer in mice, which can inhibit cancer cells by changing macrophage polarization rather than directly act on the cancer cells. It is also clarify that the benefit of Q11 may associated with the IL-6/STAT3 and MAPK/ERK pathways. The data demonstrate that CYP2E1 may be a novel inflammatory target and that Q11 is effective on lung cancer by regulation of the inflammatory microenvironment. These findings provide a molecular basis for targeting CYP2E1 and illustrate the potential druggability of the CYP2E1 inhibitor Q11.
Insights
Lung cancer inflammation is targeted by a new drug, Q11. This inhibitor of Cytochrome P450 2E1 (CYP2E1) shows promise in treating non-small cell lung cancer by modulating the tumor microenvironment.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Chronic inflammation is linked to lung cancer, but effective anti-inflammatory treatments are lacking.
- Cytochrome P450 2E1 (CYP2E1) is implicated in inflammatory responses and its levels are elevated in non-small cell lung cancer (NSCLC) tissues.
- Targeting the inflammatory microenvironment presents a potential therapeutic strategy for lung cancer.
Purpose of the Study:
- To investigate the role of CYP2E1 in lung cancer development and progression.
- To evaluate the efficacy of a novel CYP2E1 inhibitor, Q11, in treating lung cancer.
- To elucidate the mechanisms by which Q11 exerts its anti-cancer effects.
Main Methods:
- Analysis of CYP2E1 expression in peritumoral tissues of NSCLC patients.
- Assessment of lung tumor growth in wild-type and Cyp2e1 knockout mice.
- In vivo and in vitro studies to evaluate the therapeutic effects of Q11 on lung cancer.
- Investigation of Q11's impact on macrophage polarization and related signaling pathways (IL-6/STAT3, MAPK/ERK).
Main Results:
- CYP2E1 expression was significantly elevated in the peritumoral tissue of NSCLC patients.
- Lung tumor growth was significantly reduced in Cyp2e1 knockout mice.
- The novel CYP2E1 inhibitor Q11 demonstrated significant efficacy in reducing lung tumor growth in mice.
- Q11 inhibited lung cancer progression by altering macrophage polarization, not by directly targeting cancer cells.
- Q11's therapeutic benefits were associated with modulation of the IL-6/STAT3 and MAPK/ERK signaling pathways.
Conclusions:
- CYP2E1 is a potential novel inflammatory target for lung cancer therapy.
- The CYP2E1 inhibitor Q11 effectively treats lung cancer in a mouse model by regulating the inflammatory microenvironment.
- Q11 represents a promising therapeutic candidate for non-small cell lung cancer, highlighting the druggability of CYP2E1 inhibitors.
More Related Videos
07:39The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...